This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enanga, B.
Right arrow Articles by Barrett, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enanga, B.
Right arrow Articles by Barrett, M. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2003, p. 3368-3370, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3368-3370.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activity of Megazol, a Trypanocidal Nitroimidazole, Is Associated with DNA Damage

Bertin Enanga,1 Mark R. Ariyanayagam,2 Mhairi L. Stewart,1 and Michael P. Barrett1*

Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ,1 Division of Biological Chemistry and Molecular Microbiology, School of Life Sciences, Wellcome Trust Biocentre, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom2

Received 1 May 2003/ Returned for modification 19 June 2003/ Accepted 18 July 2003


arrow
ABSTRACT
 
DNA damage associated with the trypanocidal activity of megazol [2-amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole] was shown in experiments in which DNA repair-deficient RAD51-/- Trypanosoma brucei mutants were found to be hypersensitive to the drug. Parasites resistant to megazol were selected and showed modest cross-resistance to other trypanocides, although neither drug efflux nor changes to intracellular thiols correlated with resistance.


arrow
TEXT
 
New drugs are urgently required for treatment of human African trypanosomiasis (22). One compound with promise is megazol (5, 12, 13, 18), a nitroheterocyclic compound that forms a nitro radical anion upon reduction (31). Megazol appears to enter Trypanosoma brucei via passive diffusion (3), but little is known about its mode of action. We determined the effect of megazol in assays that measured oxidative and reductive stress. We also selected parasites resistant to megazol in order to assess cellular changes associated with resistance.

Bloodstream forms (17) and procyclic forms (6) of T. brucei brucei (strain 427) were cultivated by using standard techniques. Assays measuring drug sensitivity were carried out to determine the drug concentration producing a 50% decrease in cell proliferation (IC50) and the resistance factor (average ratio of the IC50 for a resistant clone to the IC50 for a wild-type clone). The Alamar Blue test (28) was used for bloodstream forms, while cell counting by using an improved Neubauer chamber was required for procyclics. For procyclic cells the IC50 of megazol was 0.28 ± 0.01 µM, and for bloodstream forms the IC50 was 0.15 ± 0.02 µM.

To induce megazol resistance in vitro, trypanosomes were exposed to drug concentrations that doubled every 2 weeks, starting at 0.008 and 0.01 µM for bloodstream forms and procyclics, respectively. After 6 months of cultivation, procyclic and bloodstream forms that tolerated 10 and 1 µM megazol, respectively, were cloned by limiting dilution.

The IC50 for the cloned, resistant, procyclic line was 29.24 ± 3.2 µM (105-fold-reduced sensitivity), while the IC50 for the bloodstream form line was 3.2 ± 0.48 µM (21-fold-reduced sensitivity).

Cross-resistance to megazol and other trypanocides was also studied (Table 1). Moderate levels of cross-resistance to two nitroheterocyclic trypanocides, the nitrofuran nifurtimox and the nitroimidazole benznidazole, were detected. Significant, albeit low-level, cross-resistance to the melaminophenyl arsenical compounds cymelarsan, melarsen oxide, and melarsoprol, the diamidine compounds pentamidine and berenil, and suramin was also observed.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Cross-resistance of bloodstream and procyclic forms of T. brucei brucei strain 427 to megazol and other trypanocidesa

Verapamil (20), PAK-104P (7), and two phenothiazine derivatives (prochlorperazine and trifluoperazine) (14) all inhibit cellular extrusion pumps but, when used at 5 µM, failed to reverse megazol resistance in T. brucei. Efflux pumps are thus unlikely to play a significant role in the megazol resistance characterized here.

It was recently shown that megazol exposure reduces trypanothione levels in Trypanosoma cruzi (23). Bloodstream form T. brucei obtained from infected Wistar rats (21) and procyclic forms grown in vitro (6) were resuspended at a concentration of 107 cells ml-1 in culture medium. Megazol (0.15 to 30 µM) or buthionine sulfoximine (BSO; 10 to 20 µM) was added to the parasite suspensions, and the suspensions were incubated for 2 h. Reduced thiol levels in control and drug-treated parasites were then determined by derivatization with monobromobimane (thiolyte) and separation by high-pressure liquid chromatography as previously described (30).

BSO (16) reduces glutathione (2) and trypanothione (15) levels in trypanosomatids. When added to cell cultures 24 h prior to evaluation of IC50s, BSO enhanced the susceptibilities of both wild-type and megazol-resistant trypanosomes to megazol. At 10 and 20 µM, respectively, BSO caused the IC50 for wild-type procyclics to drop from 0.28 to 0.14 ± 0.02 µM and that for resistant cells to drop from 29.24 to 7.33 ± 0.56 µM. With bloodstream forms, the IC50 for wild-type cells shifted from 0.15 to 0.07 ± 0.01 µM while that for resistant cells shifted from 3.2 to 1.03 ± 0.03 µM. The concentration of BSO could not exceed 20 µM since BSO is highly toxic to T. brucei (IC50s were 15.15 ± 0.22 µM and 11 ± 0.39 µM for procyclic and bloodstream forms, respectively), although related parasitic trypanosomatids T. cruzi (26) and Leishmania (19) can tolerate doses of BSO of 1 mM. The BSO effect was greater in resistant than in wild-type T. brucei.

The effects of BSO and megazol (used at their in vitro IC50s) on the combined thiol levels (total levels of glutathione, trypanothione, and glutathionylspermidine and, measurable only in procyclics [1], of ovothiol) in wild-type and resistant trypanosomes of both forms were determined. Megazol treatment, for 2 h, did not have a significant impact on thiol content in bloodstream or procyclic forms, while BSO, at the concentrations used here, affected only the thiol content of procyclic forms (reducing it about twofold from 3.2 nmol [108 cells]-1).

No significant difference in total thiol levels was observed between wild-type and resistant forms, indicating that alterations to thiol levels are not involved in the development of resistance characterized here.

Nitroheterocyclic compounds are generally believed to exert their cytotoxic effects only after activation by single electron reduction of their corresponding nitro anion radicals (27). In bacteria, the toxic effects of metronidazole are accompanied by damage to DNA (25, 29) and cells defective in DNA repair become hypersensitive to the action of metronidazole (11). A principal enzyme involved in eukaryotic DNA repair is RAD51. T. brucei mutants lacking this enzyme (24) were hypersensitive to megazol, indicating that the toxic effects of megazol are accompanied by damage to DNA (Table 2). In contrast, the susceptibility of RAD51 deletion mutants to the trypanocidal nitrofuran nifurtimox was similar to that of wild-type cells. N-acetylcysteine (NAC) antagonizes oxidative stress by interacting with a number of the reduced oxygen species (4, 8). When coadministered at 0.5 mM (the highest concentration at which no detrimental effect on trypanosomes was induced by this compound), NAC had no antagonistic effect on the action of megazol while it did have a modest protective effect against the action of nifurtimox (Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Activity of megazol against wild-type and RAD51-/- T. brucei bloodstream formsa

The activity of nifurtimox in T. brucei therefore appears to be mediated through reduced oxygen species, produced during futile redox cycling with reduced drug. Megazol's activity, however, derives from direct damage exerted by the reduced megazol nitro anion radical derivatives. In T. cruzi, nifurtimox is also known to exert its activity through redox cycling (9, 10). Recently it was shown that nifurtimox stimulated an increase in oxygen uptake into T. cruzi cells while megazol did not (23). Thus, experiments using different approaches and different species of trypanosomes indicate that the activities of the nitrofuran nifurtimox and the nitroimidazole megazol arise through different mechanisms.


arrow
ACKNOWLEDGMENTS
 
Bertin Enanga was a Wellcome Trust Traveling Fellow.

The excellent assistance of Flora Logan (funded by a Society for General Microbiology summer studentship) and Janice Brock is gratefully acknowledged. Richard McCulloch (University of Glasgow) kindly donated the RAD51-/- strain of T. brucei.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: University of Glasgow, Institute of Biomedical and Life Sciences, Division of Infection and Immunity, The Joseph Black Building, Glasgow G12 8QQ, United Kingdom. Phone and fax: 44-141-330-6904. E-mail: m.barrett{at}bio.gla.ac.uk. Back


arrow
REFERENCES
 
    1
  1. Ariyanayagam, M. R., and A. H. Fairlamb. 2001. Ovothiol and trypanothione as antioxidants in trypanosomatids. Mol. Biochem. Parasitol. 115:189-198.[CrossRef][Medline]
    2. 2
  2. Arrick, B. A., O. W. Griffith., and A. Cerami. 1981. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J. Exp. Med. 153:720-725.[Abstract/Free Full Text]
    3. 3
  3. Barrett, M. P., A. H. Fairlamb, B. Rousseau, G. Chauviere, and J. Perie. 2000. Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochem. Pharmacol. 59:615-620.[CrossRef][Medline]
    4. 4
  4. Benrahmoune, M., P. Therond, and Z. Abedinzadeh. 2000. The reaction of superoxide radical with N-acetylcysteine. Free Radic. Biol. Med. 29:775-782.[CrossRef][Medline]
    5. 5
  5. Bouteille, B., A. Marie-Daragon, G. Chauviere, C. de Albuquerque, B Enanga, M. L. Darde, J. M. Vallat, J. Perie, and M. Dumas. 1995. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop. 60:73-80.[CrossRef][Medline]
    6. 6
  6. Brun, R., and M. Schonenberger. 1979. Cultivation and in vitro cloning of procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop. 36:289-292.[Medline]
    7. 7
  7. Chuman, Y., Z. S. Chen, K. Seto, T. Sumizawa, T. Furukawa, A. Tani, M. Haraguchi, K. Niwa, K. Yamada, T. Aikou, and S. Akiyama. 1998. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett. 129:69-76.[CrossRef][Medline]
    8. 8
  8. Cotgreave, I. A. 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv. Pharmacol. 38:205-227.
    9. 9
  9. Docampo, R., and A. O. Stoppani. 1979. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys. 197:317-321.[CrossRef][Medline]
    10. 10
  10. Docampo, R., S. N. Moreno, A. O. Stoppani, W. Leon, F. S. Cruz, F. Villalta, and R. F. Muniz. 1981. Mechanism of nifurtimox toxicity in different forms of Trypanosoma cruzi. Biochem. Pharmacol. 30:1947-1951.[CrossRef][Medline]
    11. 11
  11. Elizondo, G., M. E. Gonsebatt, A. M. Salazar, I. Lares, P. Santiago, J. Herrera, E. Hong, and P. Ostrosky-Wegman. 1996. Genotoxic effects of metronidazole. Mutat. Res. 370:75-80.[CrossRef][Medline]
    12. 12
  12. Enanga, B., M. Keita, G. Chauviere, M. Dumas, and B. Bouteille. 1998. Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice. Trop. Med. Int. Health 3:736-741.[Medline]
    13. 13
  13. Enanga, B., J. M. Ndon, H. Boudra, L. Debrauwer, G. Dubreuil, B. Bouteille, G. Chauviere, C. Labat, M. Dumas, J. Perie, and G. Houin. 2000. Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis. Preliminary study. Arzneim.-Forsch. 50:158-162.
    14. 14
  14. Essodaigui, M., F. Frezard, E. S. Moreira, F. Dagger, and A. Garnier-Suillerot. 1999. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol. Biochem. Parasitol. 100:73-84.[CrossRef][Medline]
    15. 15
  15. Fairlamb, A. H., and A. Cerami. 1992. Metabolism and functions of trypanothione in the kinetoplastida. Annu. Rev. Microbiol. 46:695-729.[CrossRef][Medline]
    16. 16
  16. Griffith, O. W., and A. Meister. 1979. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254:7558-7560.[Abstract/Free Full Text]
    17. 17
  17. Hirumi, H., and K. Hirumi. 1989. Continuous cultivation of Trypanosoma brucei brucei bloodstream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989.[CrossRef][Medline]
    18. 18
  18. Jennings, F. W., G. Chauviere, C. Viode, and M. Murray. 1996. Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol. Trop. Med. Int. Health 1:363-366.[CrossRef][Medline]
    19. 19
  19. Kapoor, P., M. Sachdev, and R. Madhubala. 2000. Inhibition of glutathione synthesis as a chemotherapeutic strategy for leishmaniasis. Trop. Med. Int. Health 5:438-442.[CrossRef][Medline]
    20. 20
  20. Kaur, J., and C. S. Dey. 2000. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil. Biochem. Biophys. Res. Commun. 271:615-619.[CrossRef][Medline]
    21. 21
  21. Lanham, S. M., and D. G. Godfrey. 1970. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp. Parasitol. 28:521-534.[CrossRef][Medline]
    22. 22
  22. Legros, D., G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, and P. Buscher. 2002. Treatment of human African trypanosomiasis—present situation and needs for research and development. Lancet Infect. Dis. 2:437-440.[CrossRef][Medline]
    23. 23
  23. Maya, J. D., S. Bollo, L. J. Nunez-Vergara, J. A. Squella, Y. Repetto, A. Morello, J. Perie, and G. Chauviere. 2003. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol. 65:999-1006.[CrossRef][Medline]
    24. 24
  24. McCulloch, R., and J. D. Barry. 1999. A role for RAD51 and homologous recombination in Trypanosoma brucei antigenic variation. Genes Dev. 13:2875-2888.[Abstract/Free Full Text]
    25. 25
  25. Mendz, G. L., and F. Megraud. 2002. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol. 10:370-375.[CrossRef][Medline]
    26. 26
  26. Mocanda, C., Y. Repetto, J. Aldunate, M. E. Letelier, and A. Morello. 1989. Role of glutathione in the susceptibility of Trypanosoma cruzi to drugs. Comp. Biochem. Physiol. 94C:87-91.
    27. 27
  27. Moreno, S. N., and R. Docampo. 1985. Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis. Environ. Health Perspect. 64:199-208.[Medline]
    28. 28
  28. Raz, B., M. Iten, Y. Grether-Buhler, R. Kaminsky, and R. Brun. 1997. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop. 68:139-147.[CrossRef][Medline]
    29. 29
  29. Sander, P., K. G. Papavinasasundaram, T. Dick, E. Stavropoulos, K. Ellrott, B. Springer, M. J. Colston, and E. C. Böttger. 2001. Mycobacterium bovis BCG recA deletion mutant shows increased susceptibility to DNA-damaging agents but wild-type survival in a mouse infection model. Infect. Immun. 69:3562-3568.[Abstract/Free Full Text]
    30. 30
  30. Shim, H., and A. H. Fairlamb. 1988. Levels of polyamines, glutathione and glutathione-spermidine conjugates during growth of the insect trypanosomatid Crithidia fasciculata. J. Gen. Microbiol. 134:807-817.[Abstract/Free Full Text]
    31. 31
  31. Viode, C., N. Bettach, N. Cenas, R. L. Krauth-Siegel, G. Chauviere, N. Bakalara, and J. Perie. 1999. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol. 57:549-557.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, October 2003, p. 3368-3370, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3368-3370.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Faundez, M., Lopez-Munoz, R., Torres, G., Morello, A., Ferreira, J., Kemmerling, U., Orellana, M., Maya, J. D. (2008). Buthionine Sulfoximine Has Anti-Trypanosoma cruzi Activity in a Murine Model of Acute Chagas' Disease and Enhances the Efficacy of Nifurtimox. Antimicrob. Agents Chemother. 52: 1837-1839 [Abstract] [Full Text]  
  • Stewart, M. L., Boussard, C., Brun, R., Gilbert, I. H., Barrett, M. P. (2005). Interaction of Monobenzamidine-Linked Trypanocides with the Trypanosoma brucei P2 Aminopurine Transporter. Antimicrob. Agents Chemother. 49: 5169-5171 [Abstract] [Full Text]  
  • Faundez, M., Pino, L., Letelier, P., Ortiz, C., Lopez, R., Seguel, C., Ferreira, J., Pavani, M., Morello, A., Maya, J. D. (2005). Buthionine Sulfoximine Increases the Toxicity of Nifurtimox and Benznidazole to Trypanosoma cruzi. Antimicrob. Agents Chemother. 49: 126-130 [Abstract] [Full Text]  
  • Stewart, M. L., Bueno, G. J., Baliani, A., Klenke, B., Brun, R., Brock, J. M., Gilbert, I. H., Barrett, M. P. (2004). Trypanocidal Activity of Melamine-Based Nitroheterocycles. Antimicrob. Agents Chemother. 48: 1733-1738 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enanga, B.
Right arrow Articles by Barrett, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enanga, B.
Right arrow Articles by Barrett, M. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»